Lilly, Boehringer Ingelheim collaborating on clinical trial

By Melissa Fassbender contact

- Last updated on GMT

Enrollment is set to begin late this year. (Image: iStock)
Enrollment is set to begin late this year. (Image: iStock)

Related tags: Boehringer ingelheim, Cell cycle, Signal transduction

Eli Lilly and Company and Boehringer Ingelheim have announced that they are collaborating on a clinical trial in metastatic breast cancer.

The Ph1b study will evaluate abemaciclib (LY2835219), Lilly's cyclin-dependent kinase (CDK) 4 and CDK 6 inhibitor, in combination with BI 836845, Boehringer Ingelheim's insulin-like growth factor (IGF)-1/IGF-2 ligand neutralizing antibody.

Following results from the Ph 1b trial, the collaboration may extend to Ph II trials in patients with HR+, HER2- mBC and other solid tumors.

According to Lilly, “The rationale for the collaboration is based upon the hypothesis that these two agents, in combination, could offer a more complete pathway interference and could potentially prolong cell cycle arrest. For HR+, HER2- mBC patients, this could translate to a reversal of resistance to hormone therapy​.”

Boehringer Ingelheim will be the sponsor of the study program and enrollment is set to begin late this year.

Lilly is not disclosing any additional details at this point.

Related topics: Clinical Development, Phase I-II

Related news

Show more

Related products

RACE Act Prompts Pediatric Oncology Trials

RACE Act Prompts Pediatric Oncology Trials

PRA Health Sciences | 04-May-2020 | Technical / White Paper

Many providers prescribe drugs off-label to pediatric patients, even though there have been few pediatric trials for many of these drugs. In response,...

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Baxter BioPharma Solutions | 01-Mar-2020 | Technical / White Paper

Recent market reports suggest increasing product niches, which may lead to decreasing numbers of units per product, making dedicated facilities less practical....

What do big pharma companies spend on R&D?

What do big pharma companies spend on R&D?

Zymewire | 15-Aug-2019 | Technical / White Paper

The free Big Pharma R&D Spend report examines the financial performance and research & development investments of the top 25 pharmaceutical companies...

Related suppliers

Follow us

Products

View more

Webinars